Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 3/20 | 0.37 |
| ▸ | CLK3 | P49761 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505370 | 0.76 | HPGD (0.45) | DAOACHECDK4CCND1PARP1 | |
| SCHEMBL27129778 | 0.74 | DAO (0.44) | DAOPARP1MAPTSNCAADORA3 | |
| SCHEMBL1853725 | 0.70 | DAO (0.53) | DAOACHEPDE3BPDE3ACDK4 | |
| SCHEMBL191244 | 0.69 | HPGD (0.46) | DAOACHEMAPT | |
| Hydrochloric Acid SCHEMBL8478843 | 0.68 | HPGD (0.45) | DAOACHEMAPT | |
| Iodide SCHEMBL8481287 | 0.68 | HPGD (0.45) | DAOACHEMAPT | |
| SCHEMBL31691908 | 0.66 | DAO (0.53) | DAOACHEPDE3BPDE3ACDK4 | |
| SCHEMBL28809999 | 0.66 | DAO (0.53) | DAOACHEPDE3BPDE3ACDK4 | |
| SCHEMBL20004291 | 0.66 | DAO (0.53) | DAOACHEPDE3BPDE3ACDK4 | |
| SCHEMBL28383003 | 0.66 | DAO (0.53) | DAOACHEPDE3BPDE3ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932642-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-b][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11932642-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-b][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11932642-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-b][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932642-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-b][1,6]naphthyridines as CK2 inhibitors | CKS2, CKS1B, CDK2 | DAO 2484/4885ACHE 549/4885PDE3B 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.